AbbVie's Acquisition of Shire Could Save $8 Billion in Taxes - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

AbbVie's Acquisition of Shire Could Save $8 Billion in Taxes



According to GlobalData, a research and consulting firm, AbbVie’s recent $54 billion acquisition of Shire and subsequent relocation to Ireland will mean substantial tax savings for the US pharmaceutical giant.

Aparna Krishnan, MS, GlobalData’s analyst, and Joshua Owide, GlobalData’s director of Healthcare Industry Dynamics, said the rational for the deal consisted of a mix of portfolio diversification, operating cost synergies, and tax savings. Shire, which itself relocated to Ireland from the UK back in 2008, has since seen a notable drop in its tax expenses, with a five-year average effective tax rate (ETR) of 20.6% between 2008 and 2013, compared with 36.9% in 2008. By comparison, AbbVie’s ETR was 22.6% in 2013.

In terms of underlying assets, Shire will provide AbbVie with a portfolio that includes a number of niche drugs used in orphan diseases. According to GlobalData, the particular importance of Humira to AbbVie’s business should not be understated, as the drug accounted for 56.7% of the company’s top-line sales in 2013.

“Humira could face competition from adalimumab biosimilars as early as December 2016 in the US and April 2018 in other markets. However, even after assuming the entry of these treatments, Humira will remain AbbVie’s leading franchise far into the future, with a net present value of $37.6 billion and a free cash flow of over $60 billion through 2029,” adds Owide.

Source: GlobalData

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
41%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here